JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

IQVIA Holdings Inc

Abrir

SetorSaúde

158.59 0.26

Visão Geral

Variação de preço das ações

24h

Atual

Mín

153.65

Máximo

159.91

Indicadores-chave

By Trading Economics

Rendimento

182M

514M

Vendas

264M

4.4B

P/E

Médio do Setor

20.898

67.147

Margem de lucro

11.778

Funcionários

93,000

EBITDA

1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+41.24% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-12B

28B

Abertura anterior

158.33

Fecho anterior

158.59

Sentimento de Notícias

By Acuity

50%

50%

201 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

IQVIA Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 23:53 UTC

Ganhos

Naver Posts Weaker First-Quarter Earnings

29 de abr. de 2026, 23:41 UTC

Ações em Alta

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 de abr. de 2026, 23:55 UTC

Ganhos

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 de abr. de 2026, 23:54 UTC

Ganhos

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 de abr. de 2026, 23:52 UTC

Ganhos

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 de abr. de 2026, 23:51 UTC

Ganhos

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan 1Q Net CNY1.70B, Down 14%

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan: Power Generation Down 2.9% as of End-March

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss Narrows>000002.SZ

29 de abr. de 2026, 23:18 UTC

Ganhos

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 de abr. de 2026, 23:17 UTC

Ganhos

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 de abr. de 2026, 23:13 UTC

Ganhos

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 de abr. de 2026, 23:12 UTC

Ganhos

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 de abr. de 2026, 23:04 UTC

Ganhos

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 de abr. de 2026, 23:04 UTC

Ganhos

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparação entre Pares

Variação de preço

IQVIA Holdings Inc Previsão

Preço-alvo

By TipRanks

41.24% parte superior

Previsão para 12 meses

Média 224.54 USD  41.24%

Máximo 255 USD

Mínimo 185 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para IQVIA Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

14

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

150.68 / 153.45Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

201 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat